-
One Viking Therapeutics insider sold 57,661 shares of the company for about $1.9 million on Monday.
-
The sale represented 23.29% of Zante’s direct holdings, which fell from 247,552 to 189,891 shares, as reported.
-
All activity occurred in direct ownership — no indirect entities or family trusts were involved; the transaction included derivative context.
-
These 10 stocks could mint the next wave of millionaires ›
Greg Zante, the chief financial officer of Viking Therapeutics (NASDAQ:VKTX), reported the direct sale of 57,661 shares of the biotech in multiple open-market transactions valued at $1.9 million, according to a recent SEC Form 4 filing.
|
Metric |
Value |
|---|---|
|
Shares sold (direct) |
57,661 |
|
Transaction value |
$1.9 million |
|
Post-transaction shares (direct) |
189,891 |
|
Post-transaction value (direct ownership) |
$6.1 million |
Transaction value based on SEC Form 4 weighted average purchase price ($32.90); post-transaction value based on position value at the Monday transaction price.
-
How significant was this sale relative to Greg Zante’s recent trading activity?
This 57,661-share disposition is above his recent median sale size of 50,309 shares since May, but the high proportion (23.29%) of direct holdings impacted is explained by his diminished available share balance after prior transactions. -
Did Zante retain substantial equity exposure after the transaction?
Post-sale, Zante directly holds 189,891 shares (valued at $6.1 million as of Monday) and 91,000 options outstanding. -
How does the company’s recent stock performance contextualize this transaction?
Viking Therapeutics shares closed at $32.14 on Monday, reflecting a one-year decline of 18.62%.
|
Metric |
Value |
|---|---|
|
Price (as of Monday) |
$32.90 |
|
Market capitalization |
$3.62 billion |
|
Net income (TTM) |
($237.39 million) |
|
1-year price change |
(18.62%) |
-
Viking Therapeutics develops clinical-stage therapeutics targeting metabolic and endocrine disorders, with a pipeline including VK2809 (NASH/NAFLD), VK5211 (hip fracture recovery), VK0612 (type 2 diabetes), and VK0214 (X-linked adrenoleukodystrophy).
-
The company operates a research-driven business model focused on the development and potential future commercialization or licensing of proprietary drug candidates.
-
Primary customers will include healthcare providers, hospitals, and specialty clinics treating metabolic, endocrine, and rare disease patients, pending regulatory approvals.
Viking Therapeutics is a clinical-stage biotechnology company focused on advancing novel therapies for metabolic and endocrine diseases. With a lean team and a diversified pipeline, the company aims to address significant unmet medical needs through innovative small molecule therapeutics. Its strategic emphasis on selective receptor modulators positions it to compete in high-value specialty pharmaceutical markets as its assets progress through clinical development.